Skip to main content
TipRanks
Go Ultimate75% OFF

Dyne Therapeutics (DYN) Drug Pipeline

489 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Zeleciment BasivarsenDm1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (Dm1), Steinert Disease, SteinertPhase IIIRecruitingEfficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Mar 17, 2026―
Dyne-251Duchenne Muscular Dystrophy (Dmd)phase1AndPhase2Active Not RecruitingSafety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingAug 30, 2022―
Dyne-101Myotonic Dystrophy Type 1 (Dm1)phase1AndPhase2RecruitingSafety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1Jul 28, 2022

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Dyne Therapeutics, Inc. (DYN) have in its pipeline
Dyne Therapeutics DYN is currently developing the following drugs: Zeleciment Basivarsen, Dyne-251, Dyne-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.